Compare INSG & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INSG | MOLN |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.9M | 151.2M |
| IPO Year | 2000 | 2021 |
| Metric | INSG | MOLN |
|---|---|---|
| Price | $11.40 | $4.09 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $15.33 | $3.75 |
| AVG Volume (30 Days) | ★ 167.7K | 4.3K |
| Earning Date | 02-19-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $165,876,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.34 | $999.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.24 | $3.36 |
| 52 Week High | $18.11 | $5.41 |
| Indicator | INSG | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 46.14 |
| Support Level | $11.49 | $3.97 |
| Resistance Level | $12.71 | $4.28 |
| Average True Range (ATR) | 0.68 | 0.15 |
| MACD | 0.19 | -0.02 |
| Stochastic Oscillator | 55.38 | 26.22 |
Inseego Corp is into the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by applications software and cloud services designed to enable customers to easily analyze data insights and configure and manage their hardware. It generates maximum revenue from United States and Canada. The company also has a presence in Australia and Europe (including United Kingdom).
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.